Suppression of recurrent genital herpes infections with lithium carbonate: a randomized, placebo-controlled trial

J. D. Amsterdam, G. Maislin, L. Potter, R. Giuntoli, H. Koprowski

Research output: Research - peer-reviewArticle

Abstract

Preliminary observations indicate that lithium carbonate may have an anti-herpes simplex virus activity. We conducted a randomized, double-blind, placebo-controlled trial of oral lithium therapy in ten healthy women with recurrent genital herpes infections. The duration of the study was 18 months, i.e., 12 months of lithium and 6 months of placebo either before or after lithium therapy. During 1 year of lithium treatment at a daily dose of 587 ± 49 mg (mean ± SD) and an average plasma lithium level of 0.51 mmol/l, we observed a 3.2% average monthly reduction in the number of herpes infections (p=0.09). Moreover, we observed a 5.1% average monthly reduction in the duration of each episode (p

LanguageEnglish (US)
Pages17-25
Number of pages9
JournalLithium
Volume2
Issue number1
StatePublished - 1991
Externally publishedYes

Fingerprint

Lithium Carbonate
Herpes Genitalis
Lithium
Randomized Controlled Trials
Placebos
Infection
Therapeutics
Simplexvirus

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Amsterdam, J. D., Maislin, G., Potter, L., Giuntoli, R., & Koprowski, H. (1991). Suppression of recurrent genital herpes infections with lithium carbonate: a randomized, placebo-controlled trial. Lithium, 2(1), 17-25.

Suppression of recurrent genital herpes infections with lithium carbonate : a randomized, placebo-controlled trial. / Amsterdam, J. D.; Maislin, G.; Potter, L.; Giuntoli, R.; Koprowski, H.

In: Lithium, Vol. 2, No. 1, 1991, p. 17-25.

Research output: Research - peer-reviewArticle

Amsterdam, JD, Maislin, G, Potter, L, Giuntoli, R & Koprowski, H 1991, 'Suppression of recurrent genital herpes infections with lithium carbonate: a randomized, placebo-controlled trial' Lithium, vol 2, no. 1, pp. 17-25.
Amsterdam JD, Maislin G, Potter L, Giuntoli R, Koprowski H. Suppression of recurrent genital herpes infections with lithium carbonate: a randomized, placebo-controlled trial. Lithium. 1991;2(1):17-25.
Amsterdam, J. D. ; Maislin, G. ; Potter, L. ; Giuntoli, R. ; Koprowski, H./ Suppression of recurrent genital herpes infections with lithium carbonate : a randomized, placebo-controlled trial. In: Lithium. 1991 ; Vol. 2, No. 1. pp. 17-25
@article{4406eb9df520458a82fb626a7fb8b15b,
title = "Suppression of recurrent genital herpes infections with lithium carbonate: a randomized, placebo-controlled trial",
abstract = "Preliminary observations indicate that lithium carbonate may have an anti-herpes simplex virus activity. We conducted a randomized, double-blind, placebo-controlled trial of oral lithium therapy in ten healthy women with recurrent genital herpes infections. The duration of the study was 18 months, i.e., 12 months of lithium and 6 months of placebo either before or after lithium therapy. During 1 year of lithium treatment at a daily dose of 587 ± 49 mg (mean ± SD) and an average plasma lithium level of 0.51 mmol/l, we observed a 3.2% average monthly reduction in the number of herpes infections (p=0.09). Moreover, we observed a 5.1% average monthly reduction in the duration of each episode (p",
author = "Amsterdam, {J. D.} and G. Maislin and L. Potter and R. Giuntoli and H. Koprowski",
year = "1991",
volume = "2",
pages = "17--25",
journal = "Lithium",
issn = "0954-1381",
number = "1",

}

TY - JOUR

T1 - Suppression of recurrent genital herpes infections with lithium carbonate

T2 - Lithium

AU - Amsterdam,J. D.

AU - Maislin,G.

AU - Potter,L.

AU - Giuntoli,R.

AU - Koprowski,H.

PY - 1991

Y1 - 1991

N2 - Preliminary observations indicate that lithium carbonate may have an anti-herpes simplex virus activity. We conducted a randomized, double-blind, placebo-controlled trial of oral lithium therapy in ten healthy women with recurrent genital herpes infections. The duration of the study was 18 months, i.e., 12 months of lithium and 6 months of placebo either before or after lithium therapy. During 1 year of lithium treatment at a daily dose of 587 ± 49 mg (mean ± SD) and an average plasma lithium level of 0.51 mmol/l, we observed a 3.2% average monthly reduction in the number of herpes infections (p=0.09). Moreover, we observed a 5.1% average monthly reduction in the duration of each episode (p

AB - Preliminary observations indicate that lithium carbonate may have an anti-herpes simplex virus activity. We conducted a randomized, double-blind, placebo-controlled trial of oral lithium therapy in ten healthy women with recurrent genital herpes infections. The duration of the study was 18 months, i.e., 12 months of lithium and 6 months of placebo either before or after lithium therapy. During 1 year of lithium treatment at a daily dose of 587 ± 49 mg (mean ± SD) and an average plasma lithium level of 0.51 mmol/l, we observed a 3.2% average monthly reduction in the number of herpes infections (p=0.09). Moreover, we observed a 5.1% average monthly reduction in the duration of each episode (p

UR - http://www.scopus.com/inward/record.url?scp=0026022349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026022349&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 17

EP - 25

JO - Lithium

JF - Lithium

SN - 0954-1381

IS - 1

ER -